coverted ppt
TRANSCRIPT
![Page 1: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/1.jpg)
Pulmonary-Renal Syndrome
Alanna Beckman
MSIV
![Page 2: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/2.jpg)
Pulmonary-Renal Syndrome
Potentially life-threatening disorder, Diffuse alveolar hemorrhage
pulmonary capillaritis
In conjunction with Rapidly progressive glomerulonephritis
AGN/RPGN +/- lung hemorrhage is and emergency requires early diagnosis and treatment.
![Page 3: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/3.jpg)
Diffuse Alveolar Hemorrhage
Presentation of patients with DAH can range from cough with or without hemoptysis to severe respiratory distress.
Onset is usually abrupt. Suspect DAH:
Hemoptysis (Absent in 1/3 of patients) Radiographic Abnormalities (Alveolar opacities,
Interstitial opacities, Fibrosis) Unexplained drop in Hematocrit
Capillaritis: neutrophile infiltrates and hemorrhage
![Page 4: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/4.jpg)
Rapidly Progressive Glomerulonephritis Acute onset (days to weeks) Acute renal failure and oliguria (400mL/day) Renal Blood flow and GFR fall
Obstruction of the glomerular capillary lumen By infiltrating inflammatory cells Proliferating resident glomerular cells.
Intrarenal vasoconstricion and mesangial cell contraction Local imbalances of vasoconstrictors (leukotrienes, endothelins,
thromboxanes, platelet-activating factor) and vasodilators (NO, prostacyclin) in the microcirculation of the kidney.
![Page 5: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/5.jpg)
Pulmonary-Renal Syndromes
ANCA-associated vasculitides account for approximately 60%
Goodpasture's Syndrome for approximately 20% of the cases.
Other causes 20%
ANCA
GP-GN
Other
![Page 6: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/6.jpg)
![Page 7: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/7.jpg)
Work-up for GN
ANCA Anti-GBM Complement levels (C3,C4) Depending on history/clinical suspicion:
ANA ASLO BCx Cryocrit Hepatitis serologies
Renal Biopsy Immunofluorescence Electron microscopy (Light microscopy)
Consider GN mimics: thrombotic microantiopathy, cholesterol emboli, AIN, myeloma
For Pulmonary-Renal Syndrome you will also want to bx other tissues.
![Page 8: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/8.jpg)
Goodpastures
Autoimmune Autoantibodies directed against type IV collagen
RPGN and crecentic glomerulonephritis. 50-80% have lung hemorrhage. Bimodal distribution:
Typically young males (5-40years) Male:Female ratio = 6:1 Presentation in second peak, 6th decade, generally do not
have lung hemorrhage and have almost equal sex distribution.
![Page 9: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/9.jpg)
Goodpasture’s Syndrome
Common presentation: Hematuria Nephritic urinary sediment (dysmorphic RBC &/or RBC casts) Subnephrotic proteinuria (<3.5 g/24 hours) Rapidly progressive renal failure over weeks With or without pulmonary hemorrhage
Pulmonary hemorrhage, when it does occur, usually predates nephritis by weeks or months.
Lung involvement can vary from fluffy pulmonary infiltrates on CXR with mild dyspnea on exertion to potentially fatal pulmonary hemorrhage
Usually not hypertensive.
![Page 10: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/10.jpg)
GP Diagnosis
Diagnostic serologic marker is anti-GBM antibodies with a specificity for NCI domain of the alpha3 chain of type IV collagen.
These antibodies are detected in >90% of patients with anti-GBM nephritis.
RENAL BIOPSY is the GOLD STANDARD for diagnosis of anti-GBM nephritis. Light microscopy: diffuse proliferative GN with focal necrotizing
lesions and crescents in >50% of glomeruli. Immunofluorescence: linear ribbon-like deposits of IgG Electron Microscopy: inflammatory change without immune
deposits
![Page 11: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/11.jpg)
Normal Glomerulus RPGN/Crescentic GN
Immunofluoresence Microscopy: “Linear ribbon like”
deposition of IgG along GBM
![Page 12: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/12.jpg)
GP Treatment
Emergency plasmapheresis is done daily or on alternate days until anti-GBM antibodies are not detected in circulation
Prednisone (1mg/kg per day) is started simultaneously along with cyclophosphamide (2 to 3 mg/kg per day) or azathioprine (1 to 2 mg/kg per day) to suppress new synthesis of anti-GBM antibodies.
![Page 13: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/13.jpg)
GP Prognosis
Without treatment, 80% get ESRD within 1 year Early Treatment
If treatment is started early, before creatinine is over 5mg/dL, then 1 year survival is over 90%. It is 80% if renal failure is more advanced.
If patients require dialysis at time of presentation, they rarely recover renal function.
If crescents exist in >50% of glomeruli, then usually survival <2 yrs
Better response to treatment if ANCA +
![Page 14: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/14.jpg)
ANCA Vasculitis (pauci-immune)
Wegener’s Granulomatosis
Microscopic PolyangiitisChurg-Strauss Arteritis
![Page 15: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/15.jpg)
ANCA + Vasculitis (pauci-immune)
Disease Granulomas Renal Pulmonary Asthma ANCA type ANCA positive
Wegener’s granulo-matosis
+ 80% 90% - C-ANCA (anti-PR3)
90%
Microscopic polyantiitis
- 90% 50% - P-ANCA (anti-MPO)
70%
Churg-Strauss
Syndrome
+ 45% 70% + P-ANCA (anti-MPO)
50%
PR3 = Proteinase 3MPO = Myeloperoxidase (found in granules of neutrophils/monocytes)
![Page 16: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/16.jpg)
ANCA-associated small vessel vasculitis More common in Caucasian and elderly (mean age is 57
years) Usual presentation: nonspecific constitutional symptoms
and signs Lethargy Mailaise Anorexia Weight loss Fever Arthralgia Myalgias
![Page 17: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/17.jpg)
ANCA-associated small vessel vasculitis Nonspecific lab abnormalities
Rapid sedimentation rateElevated C-reactive proteinLeukocytosisThrombocytosisNormochromic/normocytic anemiaNormal complement levels (usually)
![Page 18: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/18.jpg)
C-ANCA PR3
![Page 19: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/19.jpg)
Wegener’s
Granulomatous vasculitis of the upper and lower respiratory tracts together with glomerulonephritis.
Prevalence is 3/100,000, very rare in blacks. M:F=1:1
Mean age of onset = 40 (but age of onset can vary widely)
![Page 20: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/20.jpg)
Wegener’s Pathogenesis:
Necrotizing vasculitis of small arteries and veins with granuloma formation (either intra- or extravascular).
Lung involvement typically appears as multiple bilateral, nodular cavitary infiltrates. On biopsy they reveal typical necrotizing granulomatous vasculitis.
Upper airway lesions (especially sinuses and nasopharynx) reveal inflammation, necrosis and granuloma formation.
Renal involvement can be focal and segmental glomerulitis early in the disease but typically progresses to RPGN. RARELY are granulomas seen on renal biopsy.
![Page 21: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/21.jpg)
Wegener’s
Presentation 95% have upper airway involvement
Paranasal sinus pain Purulent or bloody nasal discharge with or without nasal
mucosal ulceration. Nasal septal perforation can occur leading to saddle nose
deformity. Serous otitis media can occur as a result of blockage of
eustachian tube. 16% will have subglottic tracheal stenosis (from active
disease or scarring) which can cause airway obstruction.
![Page 22: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/22.jpg)
Wegener’s
PresentationPulmonary involvement in 85-90%
Cough, hemoptysis, dyspnea, chest discomfort. Endo-bronchial disease (from active disease or
scarring) can leads to obstruction with atelectasisRenal involvement dominates the clinical
picture If left untreated, it accounts directly or indirectly for
most mortality of the disease.
![Page 23: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/23.jpg)
Wegener’s
Diagnosis Demonstration of necrotizing granulomatous vasculitis
on tissue biopsy in a patient with compatible clinical features.
Pulmonary tissue biopsy offers the highest diagnostic yield.
Renal biopsy can confirm pauci-immune glomerulonephritis. Upper airway tissue biopsy usually shows granulomatous
inflammation with necrosis but may or may not show vasculitis.
![Page 24: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/24.jpg)
Wegener’s
Treatment Glucocorticoids (predisone 1mg/kg/day) should be
started for symptomatic improvement and then tapered over 6 months.
Cyclophosphamide (2mg/kg/day) Monitor leukocyte count to adjust dose to maintain count
above 3000/microL (neutrophile count of 1500). Gives you clinical remission without severe leukopenia and associated infectious risk.
![Page 25: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/25.jpg)
Wegener’s
TreatmentRelapse occurs in about 25% of patients.
Treatment for relapse is the same (goal is to achieve remission again).
Methotrexate or azathioprine can be given after remission is achieved and cyclophosphamide is stopped to maintain remission in patients that do relapse.
![Page 26: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/26.jpg)
P-ANCA MPO
![Page 27: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/27.jpg)
Churg-Strauss
AKA allergic angiitis and granulomatosis.
Asthma Peripheral and tissue eosinophilia Extravascular granuloma formation Vasculitis of multiple organ systems.
![Page 28: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/28.jpg)
Churg-Strauss
Incidence is estimated at 1 in 3 million. Can occur at any age (not documented in
infants). Mean age is 48yrs. M:F ratio= 1:1.2
![Page 29: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/29.jpg)
Churg-Strauss
Granulomatous reaction and eosinophil infiltration can occur in any organ in the body, but the lungs predominate. Other areas involved include: Skin Cardiovascular system Kidney Peripheral nervous system Gastrointestinal tract
![Page 30: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/30.jpg)
Churg-Strauss
PresentationPulmonary findings clearly dominate clinical
picture Severe asthma attacks and presence of pulmonary
infiltrates. Mononeuritis multiplex Allergic rhinitis and sinusitis
Heart disease (14%) = Most frequent cause of death.
![Page 31: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/31.jpg)
Churg-Strauss
PresentationSkin involvement 51%
Include purpura in addition to cutaneous and subcutaneous nodules.
Renal involvement 45% Less common than seen in Wegener’s and MPA Severe glomerulonephritis
![Page 32: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/32.jpg)
Churg-Strauss Biopsy of affected tissue (lung).
Microgranulomas, fibrinoid necrosis and throbosis of small arteries and veins (necrotizing vasculitis) with eosinophilic infiltrates.
Classification criteria (4 of 6 criteria is 85% Sensitive and 99.7% specific) Asthma Eosinophilia >10% Mono- or polyneuropathy Migratory or transitory pulm infiltrates Paranasal sinus abnormality Extravascular eosinophils on biopsy
![Page 33: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/33.jpg)
Churg-Strauss
Treatment Glucocorticoids; high dose.
Attempt to taper. Asthma makes tapering difficult, patients may need to be maintained on low-dose prednisone for years after clinical recovery from vasculitis to control asthma.
Patients who do not respond to glucocorticoids alone, can be treated with cyclophosphamide and prednisone (similar to Wegener’s treatment).
![Page 34: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/34.jpg)
P-ANCA MPO
![Page 35: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/35.jpg)
Microscopic Polyangiitis. Necrotizing vasculitis with few or no immune complexes
affecting small vessels (capillaries, venules, or arterioles).
Glomerulonephritis and pulmonary capillaritis are common in Microscopic Polyangiitis. (NO pulmonary capillaritis in PAN).
Not associated with HBV like PAN
ABSENCE of granulomatous inflammation differentiates this disease from Wegener’s granulomatosis.
![Page 36: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/36.jpg)
Microscopic Polyangiitis
Incidence not really established because it use to be included in PAN.
Age of onset is about 57 years. Slightly more occurrence in males than
females.
![Page 37: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/37.jpg)
Microscopic Polyangiitis
PresentationVascular lesion is a necrotizing inflammation
of capillaries, venules, as well as small and medium-sized arteries.
Rare immunoglobulin deposition seen in the vascular lesions.
Renal lesion is identical to that of Wegener’s granulomatosis lesion.
![Page 38: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/38.jpg)
Microscopic Polyangiitis
Renal involvement 90% Glomerulonephritis, often rapidly progressive. Can quickly lead to renal failure
Lung involvement 50% Alveolar hemorrhage (12%)= hemoptysis
Mononeuritis multiplex Gastrointestinal tract vasculitis Cutaneous vasculitis. (upper airway disease and pulmonary nodules are not
typically found - if found: suggests Wegener’s)
![Page 39: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/39.jpg)
Microscopic Polyangiitis
DiagnosisBiopsy of affected tissue.
Necrotizing pauci-immune inflammation of arterioles, capillaries and venules WITHOUT granulomas or eosinophilic infiltrates.
ANCA positive
![Page 40: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/40.jpg)
Microscopic Polyangiitis
TreatmentSimilar approach to that of Wegener’s. Relapse occurs in up to 34% of patients.
![Page 41: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/41.jpg)
![Page 42: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/42.jpg)
Differential Diagnosis for Pulmonary-Renal SyndromeGoodpasture’s DiseaseSystemic Vasculitis
Wegener’s Granulomatosis Microscopic PolyangiitisChurg-Strauss syndromeCryoglobulinemiaHenoch-Schonlein Purpura
Connective Tissue DiseasePolymyositis/DermatomyositisProgressive Systemic SclerosisSLE
Primary Glomerular DiseaseIgA nephropathyPost-Infectious GNMembranoproliferative GN
Pleural effusions/Lupus Pneumonitis + SLE GN
+ ASO titer, can continue to have pulmonary symptoms by the time renal symptoms manifest.
![Page 43: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/43.jpg)
![Page 44: Coverted PPT](https://reader035.vdocuments.mx/reader035/viewer/2022062319/55506f12b4c9052d158b497b/html5/thumbnails/44.jpg)
references
Harrison et. al, (2005), Principles of Internal Medicine, 16th Edition, McGraw-Hill, NY
Jennette J. (1997), Small Vessel Vasculitis. New England Journal of Medicine; 21: 1512-1523.
PubMed: Renal-Pulmonary Syndrome. Retrieved on (9/1/09) from: http://www.ncbi.nlm.nih.gov/pubmed/15905974
Sabatine, Marc S,(2008) Pocket Medicine, 3rd Edition, Lippincott Williams &Wilkins, Philadelphia
Toy, et.al. (2007), Case Files: Internal Medicine, Second Edition, McGraw-Hill, NY